Dorien Schepers

Dr. Dorien Schepers

University of Antwerp
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2012 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MLMark E Lindsay
Mark E Lindsay
DSDorien Schepers
Dorien Schepers
NBNikhita Ajit Bolar
Nikhita Ajit Bolar
JDJefferson J Doyle
Jefferson J Doyle
EGElena Gallo
Elena Gallo
BLBart Loeys
Bart Loeys

7 December 2013 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
GOGökce Orhan
Gökce Orhan
MBMerle Bock
Merle Bock
DSDorien Schepers
Dorien Schepers
EIElena I. Ilina
Elena I. Ilina
SRStephanie Nadine Reichel
Stephanie Nadine Reichel
SMSnezana Maljevic
Snezana Maljevic

30 September 2012 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ADAlexander J Doyle
Alexander J Doyle
JDJefferson J Doyle
Jefferson J Doyle
SBSeneca L Bessling
Seneca L Bessling
SMSamantha Maragh
Samantha Maragh
MLMark E Lindsay
Mark E Lindsay
HDHarry C Dietz
Harry C Dietz
Harry Dietz and colleagues report the identification of mutations in SKI in Shprintzen-Goldberg syndrome, which shares features with Marfan syndrome and Loeys-Dietz syndrome. SKI encodes a known repressor of TGF-β activity, and this work provides evidence for paradoxical increased TGF-β signaling as the mechanism underlying these related syndromes. Elevated transforming growth factor (TGF)-β signaling has been implicated in the pathogenesis of syndromic presentations of aortic aneurysm, including Marfan syndrome (MFS) and Loeys-Dietz syndrome (LDS)1,2,3,4. However, the location and character of many of the causal mutations in LDS intuitively imply diminished TGF-β signaling5. Taken together, these data have engendered controversy regarding the specific role of TGF-β in disease pathogenesis. Shprintzen-Goldberg syndrome (SGS) has considerable phenotypic overlap with MFS and LDS, including aortic aneurysm6,7,8. We identified causative variation in ten individuals with SGS in the proto-oncogene SKI, a known repressor of TGF-β activity9,10. Cultured dermal fibroblasts from affected individuals showed enhanced activation of TGF-β signaling cascades and higher expression of TGF-β–responsive genes relative to control cells. Morpholino-induced silencing of SKI paralogs in zebrafish recapitulated abnormalities seen in humans with SGS. These data support the conclusions that increased TGF-β signaling is the mechanism underlying SGS and that high signaling contributes to multiple syndromic presentations of aortic aneurysm.

1 February 2018 in Human Mutation
Verified
Journal Article
Open access
PDF file
DSDorien Schepers
Dorien Schepers
GTGiada Tortora
Giada Tortora
HMHiroko Morisaki
Hiroko Morisaki
GMGretchen MacCarrick
Gretchen MacCarrick
MLMark Lindsay
Mark Lindsay
BLBart Loeys
Bart Loeys
The Loeys–Dietz syndrome (LDS) is a connective tissue disorder affecting the cardiovascular, skeletal, and ocular system. Most typically, LDS patients present with aortic aneurysms and arterial tortuosity, hypertelorism, and bifid/broad uvula or cleft palate. Initially, mutations in transforming growth factor‐β (TGF‐β) receptors (TGFBR1 and TGFBR2) were described to cause LDS, hereby leading to impaired TGF‐β signaling. More recently, TGF‐β ligands, TGFB2 and TGFB3, as well as intracellular downstream effectors of the TGF‐β pathway, SMAD2 and SMAD3, were shown to be involved in LDS. This emphasizes the role of disturbed TGF‐β signaling in LDS pathogenesis. Since most literature so far has focused on TGFBR1/2, we provide a comprehensive review on the known and some novel TGFB2/3 and SMAD2/3 mutations. For TGFB2 and SMAD3, the clinical manifestations, both of the patients previously described in the literature and our newly reported patients, are summarized in detail. This clearly indicates that LDS concerns a disorder with a broad phenotypical spectrum that is still emerging as more patients will be identified. All mutations described here are present in the corresponding Leiden Open Variant Database.

16 April 2014 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
DSDorien Schepers
Dorien Schepers
ADAlexander J Doyle
Alexander J Doyle
GOGretchen Oswald
Gretchen Oswald
ESElizabeth Sparks
Elizabeth Sparks
LMLoretha Myers
Loretha Myers
LLLut Van Laer
Lut Van Laer

Verified
Journal Article
Open access
PDF file
ANAleksandra Nijak
Aleksandra Nijak
JSJohan Saenen
Johan Saenen
ALAlain J. Labro
Alain J. Labro
DSDorien Schepers
Dorien Schepers
BLBart Loeys
Bart Loeys
MAMaaike Alaerts
Maaike Alaerts
Brugada syndrome (BrS) is an inherited cardiac arrhythmia that predisposes to ventricular fibrillation and sudden cardiac death. It originates from oligogenic alterations that affect cardiac ion channels or their accessory proteins. The main hurdle for the study of the functional effects of those variants is the need for a specific model that mimics the complex environment of human cardiomyocytes. Traditionally, animal models or transient heterologous expression systems are applied for electrophysiological investigations, each of these models having their limitations. The ability to create induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs), providing a source of human patient-specific cells, offers new opportunities in the field of cardiac disease modelling. Contemporary iPSC-CMs constitute the best possible in vitro model to study complex cardiac arrhythmia syndromes such as BrS. To date, thirteen reports on iPSC-CM models for BrS have been published and with this review we provide an overview of the current findings, with a focus on the electrophysiological parameters. We also discuss the methods that are used for cell derivation and data acquisition. In the end, we critically evaluate the knowledge gained by the use of these iPSC-CM models and discuss challenges and future perspectives for iPSC-CMs in the study of BrS and other arrhythmias.